Perceptive Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Perceptive Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-786,358	Closed	-$104M	–	107
2025 Q1	$104M	Sell	786,358 -501,970	-39%	-$62.6M	3.66%	8
2024 Q4	$108M	Sell	1,288,328 -333,887	-21%	-$27.4M	2.97%	8
2024 Q3	$119M	Sell	1,622,215 -94,192	-5%	-$7.08M	2.51%	9
2024 Q2	$118M	Buy	1,716,407 +661,052	+63%	+$45.8M	2.83%	9
2024 Q1	$73M	Buy	1,055,355 +947,355	+877%	+$65.1M	1.28%	26
2023 Q4	$7.73M	Buy	+108,000	New	+$6.21M	0.17%	67
2023 Q3	–	Sell	-245,800	Closed	-$15.6M	–	108
2023 Q2	$15.6M	Buy	+245,800	New	+$15.3M	0.45%	56
2018 Q2	–	Sell	-70,000	Closed	-$1.47M	–	149
2018 Q1	$1.47M	Buy	+70,000	New	+$1.36M	0.04%	99
2017 Q4	–	Sell	-929,460	Closed	-$14.7M	–	155
2017 Q3	$14.7M	Buy	+929,460	New	+$13.6M	0.56%	44

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Perceptive Advisors's ITCI Position: Q2 2025 in Review

Perceptive Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 786,358 shares — an estimated $104M sold.

Perceptive Advisors first reported a position in ITCI in Q3 2017 and held it in 9 quarters. The position peaked at $119M in Q3 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Perceptive Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Perceptive Advisors sold 786,358 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $104M.
Perceptive Advisors first reported a position in Intra-Cellular Therapies Inc. in Q3 2017 and held it in 9 quarters.
Perceptive Advisors's Intra-Cellular Therapies Inc. position peaked at $119M in Q3 2024.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.